Skip to main content
OpenTrials

Clinical trial condition

Blood Coagulation Disorders, Inherited

Explore clinical trials studying Blood Coagulation Disorders, Inherited. Study availability and eligibility vary by location and protocol.

852 public trials 115 recruiting studies
Refine in advanced search Browse all conditions

Blood Coagulation Disorders, Inherited trial results

Completed

A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A

NCT03061201

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +6 more
Locations
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • City of Hope Medical Center Duarte, California, United States
  • Midtown Ambulatory Care Center Sacramento, California, United States
  • UC Davis Ambulatory Care Clinic Sacramento, California, United States
View all 22 locations
View Trial Details
Completed

An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B

NCT03901755

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +7 more
Locations
  • Swedish Orphan Biovitrum Research Site Brno, Czechia
  • Swedish Orphan Biovitrum Research Site Prague, Czechia
  • Swedish Orphan Biovitrum Research Site (Haemophilia Center Aghia Sophia Children's Hospital) Athens, Greece
  • Swedish Orphan Biovitrum Research Site (Laikο General Hospital of Athens) Athens, Greece
View all 29 locations
View Trial Details
Completed

To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)

NCT04770935

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Blood Platelet Disorders, +8 more
Locations
  • University of Iowa_Investigational Site Number :8400002 Iowa City, Iowa, United States
  • Hemophilia Center of Western Pennsylvania_Investigational Site Number :8400001 Pittsburgh, Pennsylvania, United States
  • Investigational Site Number :2500001 Lille, France
  • Investigational Site Number :2500002 Nantes, France
View Trial Details
Completed

A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A

NCT04161495

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +7 more
Locations
  • Investigational Site Number 920 Los Angeles, California, United States
  • Investigational Site Number 921 Los Angeles, California, United States
  • Investigational Site Number 911 San Diego, California, United States
  • Investigational Site Number 917 Gainesville, Florida, United States
View all 47 locations
View Trial Details
Completed

A Study of BAX 888 in Male Adults With Severe Hemophilia A

NCT03370172

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +6 more
Locations
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
  • Orthopaedic Hospital DBA Orthopaedic Hemophilia Treatment Center Los Angeles, California, United States
  • UC Davis Medical Center Sacramento, California, United States
  • University of Colorado Hemophilia & Thrombosis Center Aurora, Colorado, United States
View all 26 locations
View Trial Details
Completed

Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A

NCT04759131

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +6 more
Locations
  • Children's Hospital Los Angeles-Site Number:8400006 Los Angeles, California, United States
  • University of Florida-Site Number:8400009 Gainesville, Florida, United States
  • Children's Healthcare of Atlanta-Site Number:8400019 Atlanta, Georgia, United States
  • Rush University Medical Center-Site Number:8400001 Chicago, Illinois, United States
View all 40 locations
View Trial Details
Completed

Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A

NCT05248594

Conditions
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +6 more
Locations
  • Connecticut Children's Hemophilia Treatment Center - Connecticut Children's Medical Center Hartford, Connecticut, United States
  • Yale Hemophilia Treatment Center New Haven, Connecticut, United States
  • Dartmouth Hitchcock Hemophilia Center - Mary Hitchcock Memorial Hospital Lebanon, New Hampshire, United States
  • Newark Beth Israel Newark, New Jersey, United States
View Trial Details

Related conditions